MEI Pharma Identifies Potential Biomarker For Pracinostat In Bladder Cancer

 MEI Pharma Identifies Potential Biomarker For Pracinostat In Bladder Cancer

New Pre-Clinical Data Presented at AACR Annual Meeting in San Diego

PR Newswire

SAN DIEGO, April 7, 2014

SAN DIEGO, April 7, 2014 /PRNewswire/ -- MEI Pharma, Inc. (Nasdaq: MEIP), an
oncology company focused on the clinical development of novel therapies for
cancer, announced the presentation of new pre-clinical data showing the
ability of its lead drug candidate Pracinostat to inhibit bladder cancer cell
growth and induce activated transcription factor 3 (ATF-3) expression, a
potential marker of tumor response. The data were presented yesterday at the
American Association for Cancer Research (AACR) Annual Meeting in San Diego.

MEI Pharma Logo.

"These results are encouraging as they suggest a basis to explore the clinical
potential for Pracinostat in solid tumor indications," said Daniel P. Gold,
Ph.D., President and Chief Executive Officer of MEI Pharma. "In addition, this
represents an important first step toward identifying one or more valuable
biomarkers for Pracinostat, which can be included in clinical trials to
identify and predict patients who benefit from treatment, not only in bladder
cancer, but potentially in other solid tumors as well."

Previous studies have shown that decreased ATF-3 expression is associated with
tumor progression and reduced rate of survival in patients with bladder
cancer[1]. This study, conducted in collaboration with the Centre for Cancer
Research, MIMR-PHI Institute of Medical Research in Melbourne, Australia,
demonstrated that ATF-3 expression is reactivated in bladder cancer cells
treated with Pracinostat in vitro. In addition, the study showed that
Pracinostat treatment induced reactivation of ATF-3 in xenograft tumor

A copy of the poster, entitled "Activated Transcription Factor 3 (ATF-3)
Expression is a Potential Marker of Tumor Response to the HDAC Inhibitor
Pracinostat," is now available at

About Pracinostat

Pracinostat is an orally available histone deacetylase (HDAC) inhibitor that
has been tested in a number of Phase I and Phase II clinical trials in
advanced hematologic disorders and solid tumor indications. Pracinostat has
been generally well tolerated in more than 200 adult and pediatric patients to
date, with readily manageable side effects that are often associated with
drugs of this class, including fatigue. In a Phase I dose-escalation trial,
Pracinostat demonstrated evidence of single-agent activity in elderly acute
myeloid leukemia (AML) patients, including two out of 14 (14%) who achieved a
CR, with durable responses persisting 206+ and 362 days, respectively. In
addition, results from a pilot Phase II study of Pracinostat in combination
with Vidaza^® (azacitidine) in patients with advanced myelodysplastic syndrome
(MDS) showed an overall response rate of 90% (nine out of 10), including eight
patients who achieved either a CR or a CR with incomplete blood count recovery

MEI Pharma owns exclusive worldwide rights to Pracinostat.

About MEI Pharma

MEI Pharma, Inc. (Nasdaq: MEIP) is a San Diego-based oncology company focused
on the clinical development of novel therapies for cancer. The Company's lead
drug candidate is Pracinostat, a potential best-in-class, oral HDAC inhibitor
currently being developed for MDS and AML. MEI Pharma is also developing
ME-344, a mitochondrial inhibitor that has shown preliminary evidence of
single-agent activity in a first-in-human clinical study in patients with
refractory solid tumors, including eight of 21 evaluable patients (38%) who
achieved stable disease or better. In September 2013, the Company further
expanded its pipeline of drug candidates with the acquisition of PWT143, a
highly selective PI3-kinase delta inhibitor. For more information, go to

Under U.S. law, a new drug cannot be marketed until it has been investigated
in clinical trials and approved by the FDA as being safe and effective for the
intended use. Statements included in this press release that are not
historical in nature are "forward-looking statements" within the meaning of
the "safe harbor" provisions of the Private Securities Litigation Reform Act
of 1995. You should be aware that our actual results could differ materially
from those contained in the forward-looking statements, which are based on
management's current expectations and are subject to a number of risks and
uncertainties, including, but not limited to, our failure to successfully
commercialize our product candidates; costs and delays in the development
and/or FDA approval, or the failure to obtain such approval, of our product
candidates; uncertainties or differences in interpretation in clinical trial
results; our inability to maintain or enter into, and the risks resulting from
our dependence upon, collaboration or contractual arrangements necessary for
the development, manufacture, commercialization, marketing, sales and
distribution of any products; competitive factors; our inability to protect
our patents or proprietary rights and obtain necessary rights to third party
patents and intellectual property to operate our business; our inability to
operate our business without infringing the patents and proprietary rights of
others; general economic conditions; the failure of any products to gain
market acceptance; our inability to obtain any additional required financing;
technological changes; government regulation; changes in industry practice;
and one-time events. We do not intend to update any of these factors or to
publicly announce the results of any revisions to these forward-looking

[1] Yuan X, et al. ATF3 Suppresses Metastasis of Bladder Cancer by Regulating
Gelsolin-Mediated Remodeling of the Actin Cytoskeleton. Cancer Res. 2013 Jun


SOURCE MEI Pharma, Inc.

Contact: Pete De Spain, Vice President, Investor Relations & Corporate
Communications, (858) 792-3729,
Press spacebar to pause and continue. Press esc to stop.